Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975719 | 0.88 | REN (0.46) | MAPTSMPD1TTRALDH1A1CA12 | |
| SCHEMBL3374024 | 0.85 | RARB (0.51) | POLBALDH1A1RARARARBRARG | |
| SCHEMBL3372285 | 0.84 | MAPT (0.60) | CYP4A11CYP4F2MAPTSMPD1MGLL | |
| SCHEMBL15595698 | 0.84 | MAPT (0.60) | CYP4A11MAPTSMPD1MGLL | |
| SCHEMBL3371363 | 0.82 | NOTUM (0.43) | MAPTSMPD1TTRALDH1A1CA12 | |
| SCHEMBL2802839 | 0.82 | CYP4A11 (0.49) | CYP4A11CYP4F2POLBMAPTSMPD1 | |
| SCHEMBL9514148 | 0.82 | SMPD1 (0.54) | SMPD1ALDH1A1MGLL | |
| SCHEMBL8429886 | 0.81 | MAPT (0.60) | POLBMAPTALDH1A1CA12CA1 | |
| SCHEMBL12493216 | 0.81 | ALDH1A1 (0.54) | CYP4A11CYP4F2POLBMAPTTTR | |
| SCHEMBL31238673 | 0.81 | SMPD1 (0.54) | CYP4A11CYP4F2POLBMAPTSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | CYP4A11 214/4885CYP4F2 803/4885POLB 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.